Notice Number: NOT-AI-16-035

Key Dates
Release Date: March 17, 2016

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this Notice is to inform potential applicants of a change in the eligibility information in the funding opportunity announcement (FOA) RFA-AI-15-051 titled, "Consortium for Food Allergy Research: Clinical Research Units (UM1)".

Part 2. Section III. 3. Additional Information on Eligibility

Number of Applications

Current Language:
Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed.

Institutions may submit an application to both the CoFAR Leadership Center (RFA-AI-15-050) and the CoFAR Clinical Research Units (RFA-AI-15-051). However, the same clinical trial cannot be proposed in both RFAs. 

The NIH will not accept duplicate or highly overlapping applications under review at the same time.  This means that the NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101).

Revised language:

Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed. Applications are limited to one institution per application such that the PD/PI and co-investigators must be from the same institution.

Institutions may submit an application to both the CoFAR Leadership Cen ter (RFA-AI-15-050) and the CoFAR Clinical Research Units (RFA-AI-15-051). However, the same clinical trial cannot be proposed in both RFAs. 

The NIH will not accept duplicate or highly overlapping applications under review at the same time.  This means that the NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101).

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

Michael Minnicozzi, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3532
Email: [email protected]